Nuformix plc (LON:NFX – Get Free Report)’s stock price shot up 9.2% during trading on Wednesday . The company traded as high as GBX 0.38 and last traded at GBX 0.28. 139,235,969 shares were traded during trading, an increase of 275% from the average session volume of 37,120,164 shares. The stock had previously closed at GBX 0.26.
Nuformix Stock Performance
The firm has a market cap of £4.43 million, a PE ratio of -5.34 and a beta of 1.41. The company’s 50-day simple moving average is GBX 0.26 and its two-hundred day simple moving average is GBX 0.24.
Nuformix (LON:NFX – Get Free Report) last released its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) earnings per share (EPS) for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
